Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Lx-2931. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lx-2931 SCHEMBL306099 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CYP1A2 | |
| Lx-2931 SCHEMBL4382659 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CYP1A2 | |
| Lx-2931 SCHEMBL304964 | 0.99 | L3MBTL1 (0.33) | L3MBTL1CYP1A2 | |
| Lx-2931 SCHEMBL316870 | 0.99 | L3MBTL1 (0.33) | L3MBTL1CYP1A2 | |
| Lx-2931 SCHEMBL20744226 | 0.99 | L3MBTL1 (0.33) | L3MBTL1CYP1A2 | |
| Lx-2931 SCHEMBL304963 | 0.99 | L3MBTL1 (0.33) | L3MBTL1CYP1A2 | |
| Lx-2931 SCHEMBL20744228 | 0.99 | L3MBTL1 (0.33) | L3MBTL1CYP1A2 | |
| SCHEMBL316038 | 0.86 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL10069449 | 0.86 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL316037 | 0.86 | L3MBTL1 (0.30) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658682-B2 | (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone dihydrate and methods of its use | LEXICON PHARMACEUTICALS, INC. (US) | 2014-02-25 | — | — | US | claimed |
| US-20090298901-A1 | (E)-1-(4-((1R,2S,3R)-1,2,3,4-TETRAHYDROXYBUTYL)-1H-IMIDAZOL-2-YL)ETHANONE OXIME DIHYDRATE AND METHODS OF ITS USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-12-03 | — | — | US | claimed |
| US-20080275099-A1 | Solid Forms of (E)-1-(4-((1R,2S,3R)-1,2,3,4-Tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone Oxime | LEXICON PHARMACEUTICALS, INC. | 2008-11-06 | — | — | US | claimed |
| EP-2139864-B1 | METHODS OF PREPARING 1-(4-(1-HYDROXYALKYL)-1H-IMIDAZOL-2-YL)ETHANONE OXIME COMPOUNDS | LEXICON PHARMACEUTICALS INC (US) | 2015-12-02 | — | — | EP | disclosed |
| US-8658682-B2 | (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone dihydrate and methods of its use | LEXICON PHARMACEUTICALS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658682-B2 | (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone dihydrate and methods of its use | LEXICON PHARMACEUTICALS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20130109865-A1 | METHODS OF PREPARING 1-(4-((1R,2S,3R)-1,2,3,4-TETRAHYDROXYBUTYL)-1H-IMIDAZOL-2-YL)ETHANONE | LEXICON PHARMACEUTICALS, INC. | 2013-05-02 | — | — | US | disclosed |
| US-8093280-B2 | Methods of preparing imidazole-based compounds | LEXICON PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110098482-A1 | METHODS OF PREPARING 1-(4-((1R,2S,3R)-1,2,3,4-TETRAHYDROXYBUTYL)-1H-IMIDAZOL-2-YL)ETHANONE | LEXICON PHARMACEUTICALS, INC. | 2011-04-28 | — | — | US | disclosed |
| US-20110071303-A1 | METHODS OF PREPARING IMIDAZOLE-BASED COMPOUNDS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2011-03-24 | — | — | US | disclosed |
| US-7812174-B2 | Methods of preparing imidazole-based compounds | LEXICON PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20090298901-A1 | (E)-1-(4-((1R,2S,3R)-1,2,3,4-TETRAHYDROXYBUTYL)-1H-IMIDAZOL-2-YL)ETHANONE OXIME DIHYDRATE AND METHODS OF ITS USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-12-03 | — | — | US | disclosed |
| US-20090298901-A1 | (E)-1-(4-((1R,2S,3R)-1,2,3,4-TETRAHYDROXYBUTYL)-1H-IMIDAZOL-2-YL)ETHANONE OXIME DIHYDRATE AND METHODS OF ITS USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-12-03 | — | — | US | disclosed |
| US-20090298901-A1 | (E)-1-(4-((1R,2S,3R)-1,2,3,4-TETRAHYDROXYBUTYL)-1H-IMIDAZOL-2-YL)ETHANONE OXIME DIHYDRATE AND METHODS OF ITS USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-12-03 | — | — | US | disclosed |
| US-20080275099-A1 | Solid Forms of (E)-1-(4-((1R,2S,3R)-1,2,3,4-Tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone Oxime | LEXICON PHARMACEUTICALS, INC. | 2008-11-06 | — | — | US | disclosed |
| US-20080262241-A1 | Methods of Preparing Imidazole-Based Compounds | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262241-A1 | Methods of Preparing Imidazole-Based Compounds | PAICS, TOP2B, PPIP5K2 | L3MBTL1 4548/4885CYP1A2 82/4885 |
| US-20080275099-A1 | Solid Forms of (E)-1-(4-((1R,2S,3R)-1,2,3,4-Tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone Oxime | CYP2E1, OPRK1, SULT1E1 | L3MBTL1 3001/4885CYP1A2 20/4885 |
| US-20130109865-A1 | METHODS OF PREPARING 1-(4-((1R,2S,3R)-1,2,3,4-TETRAHYDROXYBUTYL)-1H-IMIDAZOL-2-YL)ETHANONE | CYP2J2, ULK3, CYP2E1 | L3MBTL1 3962/4885CYP1A2 82/4885 |
| US-20110098482-A1 | METHODS OF PREPARING 1-(4-((1R,2S,3R)-1,2,3,4-TETRAHYDROXYBUTYL)-1H-IMIDAZOL-2-YL)ETHANONE | CYP2J2, ULK3, CYP2E1 | L3MBTL1 3962/4885CYP1A2 82/4885 |
| US-20110071303-A1 | METHODS OF PREPARING IMIDAZOLE-BASED COMPOUNDS | PAICS, TOP2B, PPIP5K2 | L3MBTL1 4548/4885CYP1A2 82/4885 |
| US-20090298901-A1 | (E)-1-(4-((1R,2S,3R)-1,2,3,4-TETRAHYDROXYBUTYL)-1H-IMIDAZOL-2-YL)ETHANONE OXIME DIHYDRATE AND METHODS OF ITS USE | CYP2E1, CBR1, OXER1 | L3MBTL1 4040/4885CYP1A2 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.